When the outbreak was confirmed, fear quickly swept through the region. Memories of past epidemics returned, and health officials braced for a long and difficult response. But just two weeks later, signs of recovery have begun to emerge, thanks to the Congolese government's rapid mobilization and international support led by the World Health Organization (WHO) and key partners.
One of the most notable success factors has been the speed of the response. Within 24 hours of detecting the first case, the government declared an outbreak, setting in motion a large-scale intervention supported by WHO, Médecins Sans Frontières (MSF), UNICEF, ALIMA, WFP, IOM, and MONUSCO. Aircraft were deployed to deliver vaccines, medical teams, and supplies to Bulape the outbreak's epicenter cutting response time from days to hours.
As of September 17, there were 48 cases (38 confirmed, 10 probable) and 31 deaths. Despite the toll, over 90% of individuals who had contact with confirmed cases are now being monitored, a dramatic improvement from just 19% at the outbreak’s start. Nearly 950 contacts are under daily surveillance, enabling faster isolation and treatment, which experts say is crucial in curbing the virus’s spread.
The Ebola Treatment Centre in Bulape a 34-bed facility staffed by Congolese and international medical teams has become the heart of the response. As of mid-September, 15 patients were receiving care there. On September 15, two patients were discharged after recovering from the virus. Their release symbolized a turning point for a community that had been engulfed in anxiety.
The centre offers not only isolation but also advanced care, including fluid resuscitation, treatment for co-infections, nutritional support, and access to promising therapeutics such as monoclonal antibodies mAb114 and Inmazeb. Early treatment significantly improves survival chances, according to WHO experts.
Vaccination has also played a central role in bolstering the response. Thanks to pre-positioned supplies, vaccinations began just nine days after the outbreak was declared. Over 590 people, including more than 280 frontline workers, have already been vaccinated in Bulape and nearby areas. An additional 45,000 doses of the Ervebo vaccine have been approved for use in DRC, with the first shipment arriving in Kinshasa on September 19. Efforts are underway to establish an ultra-cold chain storage facility in Bulape to support expanded vaccine deployment.
Unlike previous outbreaks, this one has seen strong cooperation from local communities. There have been no recorded acts of hostility toward health workers, and hesitancy among families has been addressed through culturally sensitive outreach and education. Local and religious leaders have joined engagement teams to build trust and explain the benefits of seeking treatment.
The outbreak’s proximity to the Angolan border has raised fears of cross-border transmission. WHO has prioritized Angola for preparedness support, including risk assessments, simulation exercises, and contingency planning. Regional readiness is currently estimated at 57% across 11 key response pillars.
While the current response shows promise, experts caution against complacency. Ebola remains highly unpredictable, and challenges such as infrastructure limitations, difficult terrain, and food insecurity remain. Women, who make up 55% of the current caseload, are especially vulnerable due to their caregiving roles.
To mitigate economic hardships, the World Food Programme is planning general food distribution for affected households and continues to support patients with meals in treatment centres. Officials stress that the ongoing outbreak also presents a critical opportunity to invest in long-term health system resilience improving surveillance, infrastructure, and community engagement to withstand future public health threats.
Speaking to The Independent, Dr. Patrick Otim, WHO’s Emergency Response Manager, remained cautiously optimistic. He noted improvements in contact tracing and case detection but emphasized that sustained vigilance is needed. “It is too early, but we have seen significant progress. If we continue on this trajectory along with vaccine rollout, we should be able to control this outbreak as soon as possible,” he said.
As Bulape begins to see its first survivors leave the treatment centre, the community finds strength in the possibility of turning crisis into resilience. The road ahead remains challenging, but for now, hope is rising fueled by science, solidarity, and swift action.